Pharmaceutical Technology

APRIL 21, 2023

Twist Bioscience and Astellas Pharma have entered a collaboration to help the latter to discover antibodies for immunotherapies. In May 2022, they signed a research partnership and exclusive option licence agreement for the development of antibodies to reduce tumour microenvironment-mediated immunosuppression.

Antibody 264

Antibody Licensing Licensing Protein 264

Bio Pharma Dive

JULY 28, 2021

The acquisition is the third Amgen has made since March and broadens its ability to develop bispecific antibodies, a drug class of intense interest to big biotech.

Antibody 306

Antibody Drugs Development 306

Pharmaceutical Technology

FEBRUARY 19, 2024

Almirall has signed a licensing agreement for the acquisition of worldwide rights to Novo Nordisk’s IL21-hindering antibody NN-8828.

Licensing 241

Licensing Licensing Antibody 241

Pharmaceutical Technology

MARCH 16, 2023

Talem Therapeutics, a subsidiary of Immunoprecise Antibodies, has entered a multi-target artificial intelligence (AI)-driven antibody discovery collaboration with Libera Bio. The MPN Technology provides an elegant way for delivering antibodies inside tumour cells.

Antibody 262

Antibody In-Vivo Pharma Companies Protein 262

Pharmaceutical Technology

JULY 21, 2022

AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In June 2020, these antibodies, discovered at Vanderbilt University Medical Center, were licensed to AstraZeneca.

Antibody 264

Antibody Compliance Clinical Trials Clinical Trials 264

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology: Leading companies in cancer monoclonal antibody therapy. Immatics is one of the most important players concerning innovation surrounding cancer monoclonal antibody therapy.

Antibody 261

Antibody Immune Response Protein Development 261

Pharmaceutical Technology

AUGUST 24, 2023

Japan has granted a new drug substance patent for BioArctic’s monoclonal antibody (mAb), BAN0805, to treat Parkinson’s disease.

Antibody 245

Antibody Drugs 245

Bio Pharma Dive

FEBRUARY 11, 2022

Distribution of Lilly's earlier antibody treatments was halted as testing showed them ineffective against omicron. Bebtelovimab appears able to neutralize the variant, and was authorized by the FDA on Friday.

Antibody 277

Antibody 277

Pharmaceutical Technology

JULY 4, 2022

Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.

Antibody 279

Antibody Genotype Development Licensing 279

Pharmaceutical Technology

JANUARY 9, 2023

Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.

FDA Approval 246

FDA Approval Antibody Clinical Trials Clinical Trials 246

Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-influenza antibody compositions. However, not all innovations are equal and nor do they follow a constant upward trend.

Antibody 246

Antibody Vaccination Vaccine Dermatology 246

Bio Pharma Dive

DECEMBER 23, 2021

The decision follows worrisome results in lab studies that indicated omicron can evade both drugs and leaves the U.S. with fewer treatments to respond to the variant's spread.

Antibody 347

Antibody Drugs 347

Bio Pharma Dive

MAY 7, 2024

The $200 million round is the latest evidence that surging interest in autoimmune disease cell therapies could expand to include developers of bispecific antibodies, too.

Antibody 189

Antibody Development 189

Bio Pharma Dive

MAY 25, 2023

Study abstracts released Thursday give investors and analysts a better look at cancer treatments recently licensed by Merck and BioNTech as well as fresh details on other closely watched ADC candidates.

Antibody 324

Antibody Licensing Licensing Drugs 324

Bio Pharma Dive

JULY 27, 2022

The companies pitch their collaboration as a way to give young drugmakers backed by Versant a head start. “Our business is advanced by great ideas coming into the funnel,” said AbCellera’s CEO.

Antibody 336

Antibody 336

Pharmaceutical Technology

DECEMBER 9, 2024

Citryll has secured an oversubscribed Series B funding round, raising 85m ($89.8m) to advance the clinical development of CIT-013.

Development 261

Development Antibody Clinical Development 261

Bio Pharma Dive

OCTOBER 18, 2024

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

Antibody 279

Antibody Trials 279

Bio Pharma Dive

AUGUST 3, 2020

Seeking fast answers in a pandemic, Lilly will use mobile RVs to set up infusion clinics at assisted living facilities, which have become COVID-19 hot spots.

Nurses 341

Nurses Antibody Drugs 341

Bio Pharma Dive

AUGUST 9, 2024

The deal hands Merck a cancer medicine already in human testing, but that the company sees as a potential treatment for autoimmune conditions, too.

Antibody 299

Antibody Medicine 299

Bio Pharma Dive

APRIL 16, 2021

The request comes less than six months after the FDA authorized Lilly's bamlanivimab, reflecting the spread of virus variants that can elude the drug.

Antibody 340

Antibody Drugs 340

Bio Pharma Dive

APRIL 3, 2024

The startup claims to have a more efficient way to develop biologic drugs that treat disease by turning on cellular pathways, rather than blocking them.

Antibody 299

Antibody Drugs Development 299

Bio Pharma Dive

OCTOBER 7, 2020

The pharma is the first to seek emergency approval for this kind of treatment, and may quickly follow up with a second request after reporting promising data for a two-drug combination.

Antibody 338

Antibody Drugs 338

Bio Pharma Dive

JANUARY 26, 2021

The results show that drugs from both companies can help prevent or treat COVID-19 when given at the right time. But that won't mean much if barriers to use remain high.

Antibody 338

Antibody Drugs 338

Bio Pharma Dive

SEPTEMBER 16, 2020

The results, from a mid-stage study of Lilly's drug, suggest treatment helped lower virus levels, but the degree to which patients benefited remains unclear.

Antibody 328

Antibody Drugs 328

Bio Pharma Dive

SEPTEMBER 15, 2021

Deals with Regeneron and Eli Lilly will secure nearly 1.8 million additional doses of the companies' respective treatments over the next four months.

Antibody 300

Antibody Drugs 300

Bio Pharma Dive

NOVEMBER 30, 2021

While Regeneron is still testing its treatment against the new variant, the biotech is readying contingency plans, including second-generation versions of its drug.

Antibody 298

Antibody Drugs 298

Pharmaceutical Technology

MARCH 26, 2024

The approval from Japan’s Ministry of Health, Labour, and Welfare (MHLW) is based on positive results from two studies.

Antibody 246

Antibody 246

Bio Pharma Dive

JUNE 21, 2021

Final clinical trial results confirmed treatment dramatically reduced the risk of hospitalization and death among adults with mild-to-moderate COVID-19.

Antibody 312

Antibody Clinical Trials Clinical Trials Trials 312

Pharmaceutical Technology

NOVEMBER 26, 2024

The NHS will provide the monoclonal antibody Crysvita at 20 specialist centres across England for patients with XLH.

Antibody 130

Antibody 130

Pharmaceutical Technology

SEPTEMBER 4, 2024

Pfizer Ignite will support Acepodia in developing its pipeline cancer therapeutic candidates.

Antibody 246

Antibody Development 246

Pharmaceutical Technology

JUNE 21, 2024

Trial investigators anticipate that the FDA will decide on approval for linvoseltamab in relapsed/refractory multiple myeloma by the end of 2024.

Antibody 246

Antibody Trials 246

Pharmaceutical Technology

OCTOBER 21, 2024

In an exclusive interview, the CEO of ImmunoPrecise Antibodies described the benefits of rabbit monoclonal antibodies in oncology.

Antibody 130

Antibody 130

Pharmaceutical Technology

AUGUST 23, 2024

The two companies have expanded their agreement first inked in 2023, with a second ‘high-value target’ now in the crosshairs.

Antibody 237

Antibody 237

Pharmaceutical Technology

OCTOBER 3, 2024

ImmunoPrecise Antibodies, an AI-driven biotherapeutic research and technology company, has entered into a material transfer and evaluation agreement (MTEA) with Biotheus on bispecific antibodies to treat cancer.

Antibody 130

Antibody Research 130

Pharmaceutical Technology

NOVEMBER 19, 2024

Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.

Antibody 130

Antibody Licensing Licensing 130

Bio Pharma Dive

APRIL 14, 2022

Fresh trial results intensify competition with Roche to deliver the first lymphoma drug that marries antibody technology with an immunotherapy pathway.

Drugs 361

Drugs Antibody Trials 361

Pharmaceutical Technology

AUGUST 15, 2023

The biologic was able to halt disease progression in rheumatoid arthritis with the same effectiveness as gold-standard treatment Remicade.

Antibody 246

Antibody Research 246